- Home
- CNTX vs MIRA Comparison
CNTX vs MIRA Comparison
Compare CNTX & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTX | MIRA |
|---|---|---|
| Founded | 2015 | 2020 |
| Country | United States | United States |
| Employees | 15 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.5M | 43.7M |
| IPO Year | 2021 | 2023 |
Fundamental Metrics
Financial Performance| Metric | CNTX | MIRA |
|---|---|---|
| Price | $0.59 | $1.01 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $6.60 | N/A |
| AVG Volume (30 Days) | ★ 2.7M | 88.4K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.39 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.55 | $0.90 |
| 52 Week High | $3.62 | $2.45 |
Technical Indicators
Market Signals| Indicator | CNTX | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 20.39 | 51.74 |
| Support Level | N/A | $0.99 |
| Resistance Level | $1.30 | $1.22 |
| Average True Range (ATR) | 0.14 | 0.04 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 3.80 | 76.19 |
Price Performance
Historical ComparisonAbout CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.